Through an in vitro CRISPR-Cas9 screen, Belk et al. showed that elimination of ARID1A confers CD8+ T cells proliferative and cytotoxic function in vivo, leading to better anti-tumor activity [75]. This evidence concerns the gene ARID1A and neoplasm.